US President Donald Trump spoke to Defense Secretary Pete Hegseth at the Cabinet meeting at Washington, DC, US, US, on July 8, 2025 at the White House.
Kevin Lamark | Rooters
President Donald Trump On Tuesday, threatened to impose 200% on imported pharmaceuticals in the United States.
Trump said at a cabinet meeting, “They will be at a rate of 5%higher.”
But they suggested that the fee would not be implemented immediately, saying that he would “give people about a year and a half”.
Trump said, “We will give them a certain period of time to work together,” Trump said.
The President has repeatedly threatened and later changed the course of the rate proposals, so it is not guaranteed that he set up pharmaceutical tariffs at that rate. After Trump’s comments, the pharmaceutical stock was widely changed.
When his administration launched the so-called Section 232 inquiries on those products since April, Trump has been the most important comment on the pharmaceutical-specific rates from April. The Legal Rights allow the Commerce Secretary to inquire into the impact of imports on national security.
In those planned rates, pharmaceutical companies were long-awaited, many of them. Pushed back And hints that the charge can increase the costs, prevent Investment Disrupting the supply chains in the United States and the drug is at risk to patients. The industry is already navigating Trump’s Fallout Drug pricing policiesThe drug makers argue that their ability to invest in their base lines and research and development is threatened both.
Trump has said Ely Lily, Johnson and Johnson, Abiy And in the last few decades, homemade drug production has been dramatically reduced by others in the United States.
After Trump’s comments, the major pharmaceutical stock was widely changed.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Post Comment